Interim report, January–March 2005

19 May 2005 · Interim Report · Regulatory

• Net sales amounted to MSEK 1.2 (1.1) • Net loss after tax was MSEK 18.8 (loss: 8.9) • Earnings per share amounted to a loss of SEK 509.90 (loss: 260.54) • Efficacy study for OX 22 (pharmaceutical for the treatment of temporary sleep disturbances) was completed with positive results • Increased investment in diagnostic pharmaceutical – new subsidiary centered on Diabact® UBT currently under formation • Continued organizational expansion – new analytical laboratory was opened and additional expertise recruited • Dr. Nils-Otto Ahnfelt was appointed Project Director For further information, please contact: Zsolt Lavotha, President and CEO, Tel: +46-18-780 88 00, e-mail: zsolt.lavotha@orexo.se Erik Bergman, CFO, Tel: +46-18-780 88 00, e-mail: erik.bergman@orexo.se Johan Tamsen, Investor Relations, Tel: +46-733 – 25 40 10, e-mail: johan.tamsen@orexo.se Read more at www.orexo.com